DOP2011000398A - Nuevas sales de fumarato de un antagonista del receptor de histamina h3 - Google Patents
Nuevas sales de fumarato de un antagonista del receptor de histamina h3Info
- Publication number
- DOP2011000398A DOP2011000398A DO2011000398A DO2011000398A DOP2011000398A DO P2011000398 A DOP2011000398 A DO P2011000398A DO 2011000398 A DO2011000398 A DO 2011000398A DO 2011000398 A DO2011000398 A DO 2011000398A DO P2011000398 A DOP2011000398 A DO P2011000398A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- salts
- new smoke
- histamine
- receiver antagonist
- antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La descripción se refiere a sales de fumarato de 2-(ciclohexilmetil)-N-{2-[(2S)-1- metilpirrolidin-2-il]etil}-1 ,2,3,4-tetrahidroisoquinolina-7-sulfonamida, a sus composiciones farmacéuticas, procedimientos para elaborarlas y a sus métodos de uso.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22068309P | 2009-06-26 | 2009-06-26 | |
FR0959110 | 2009-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2011000398A true DOP2011000398A (es) | 2012-01-31 |
Family
ID=43386878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2011000398A DOP2011000398A (es) | 2009-06-26 | 2011-12-21 | Nuevas sales de fumarato de un antagonista del receptor de histamina h3 |
Country Status (25)
Country | Link |
---|---|
US (1) | US8664245B2 (es) |
EP (1) | EP2445899B1 (es) |
JP (1) | JP6053519B2 (es) |
KR (1) | KR101804749B1 (es) |
CN (1) | CN102803247B (es) |
AR (1) | AR077223A1 (es) |
AU (1) | AU2010264422B2 (es) |
BR (1) | BRPI1011258A2 (es) |
CA (1) | CA2766154C (es) |
CO (1) | CO6480943A2 (es) |
DO (1) | DOP2011000398A (es) |
ES (1) | ES2587064T3 (es) |
IL (1) | IL216924A0 (es) |
MA (1) | MA33378B1 (es) |
MX (1) | MX2011012824A (es) |
NZ (1) | NZ597219A (es) |
PE (1) | PE20121403A1 (es) |
PL (1) | PL2445899T3 (es) |
RU (1) | RU2537847C2 (es) |
SG (1) | SG176645A1 (es) |
TN (1) | TN2011000620A1 (es) |
TW (1) | TWI462915B (es) |
UY (1) | UY32738A (es) |
WO (1) | WO2010151611A1 (es) |
ZA (1) | ZA201108838B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR080374A1 (es) | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
WO2014012859A1 (en) * | 2012-07-19 | 2014-01-23 | Boehringer Ingelheim International Gmbh | Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof |
WO2015032966A1 (en) * | 2013-09-09 | 2015-03-12 | Sanofi | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228170A (en) | 1979-08-30 | 1980-10-14 | Smithkline Corporation | 7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds |
EP0306375A1 (fr) | 1987-08-07 | 1989-03-08 | Synthelabo | Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique |
IL89156A (en) | 1988-07-12 | 1993-05-13 | Synthelabo | Derivatives of 2-((4-piperidinyl) methyl)- 1,2,3,4- tetrahydroisoquinoline, their preparation and their application in therapeutics |
WO2001009101A1 (en) | 1999-07-29 | 2001-02-08 | EGIS Gyógyszergyár Rt. | Isoquinoline derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance |
US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
US20050154230A1 (en) | 2001-12-26 | 2005-07-14 | Bayer Healthcare Ag | Urea derivatives |
US7790231B2 (en) | 2003-07-10 | 2010-09-07 | Brewer Science Inc. | Automated process and apparatus for planarization of topographical surfaces |
FR2870846B1 (fr) * | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
AU2006228690A1 (en) * | 2005-03-31 | 2006-10-05 | Ucb Pharma S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
BRPI0709612A2 (pt) * | 2006-03-15 | 2011-07-19 | Wyeth Corp | composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i |
PE20081152A1 (es) * | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
US7846930B2 (en) * | 2007-05-18 | 2010-12-07 | Janssen Pharmaceutica Nv | Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators |
CA2693138A1 (en) * | 2007-07-16 | 2009-01-22 | Wyeth Llc | Aminoalkylazole derivatives as histamine-3 antagonists |
-
2010
- 2010-06-24 EP EP10729017.3A patent/EP2445899B1/en active Active
- 2010-06-24 RU RU2012102671/04A patent/RU2537847C2/ru not_active IP Right Cessation
- 2010-06-24 CN CN201080028665.3A patent/CN102803247B/zh not_active Expired - Fee Related
- 2010-06-24 JP JP2012517706A patent/JP6053519B2/ja not_active Expired - Fee Related
- 2010-06-24 KR KR1020117030933A patent/KR101804749B1/ko active IP Right Grant
- 2010-06-24 MX MX2011012824A patent/MX2011012824A/es not_active Application Discontinuation
- 2010-06-24 WO PCT/US2010/039731 patent/WO2010151611A1/en active Application Filing
- 2010-06-24 PE PE2011002152A patent/PE20121403A1/es not_active Application Discontinuation
- 2010-06-24 PL PL10729017T patent/PL2445899T3/pl unknown
- 2010-06-24 MA MA34475A patent/MA33378B1/fr unknown
- 2010-06-24 AU AU2010264422A patent/AU2010264422B2/en not_active Ceased
- 2010-06-24 ES ES10729017.3T patent/ES2587064T3/es active Active
- 2010-06-24 NZ NZ597219A patent/NZ597219A/xx not_active IP Right Cessation
- 2010-06-24 SG SG2011089422A patent/SG176645A1/en unknown
- 2010-06-24 CA CA2766154A patent/CA2766154C/en not_active Expired - Fee Related
- 2010-06-24 BR BRPI1011258A patent/BRPI1011258A2/pt not_active IP Right Cessation
- 2010-06-24 AR ARP100102239A patent/AR077223A1/es unknown
- 2010-06-25 UY UY0001032738A patent/UY32738A/es not_active Application Discontinuation
- 2010-06-25 TW TW099120734A patent/TWI462915B/zh not_active IP Right Cessation
-
2011
- 2011-12-01 ZA ZA2011/08838A patent/ZA201108838B/en unknown
- 2011-12-05 TN TNP2011000620A patent/TN2011000620A1/en unknown
- 2011-12-08 US US13/314,772 patent/US8664245B2/en not_active Expired - Fee Related
- 2011-12-12 IL IL216924A patent/IL216924A0/en unknown
- 2011-12-21 DO DO2011000398A patent/DOP2011000398A/es unknown
- 2011-12-23 CO CO11177476A patent/CO6480943A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2010264422B2 (en) | 2014-12-18 |
TW201103911A (en) | 2011-02-01 |
CN102803247A (zh) | 2012-11-28 |
ES2587064T3 (es) | 2016-10-20 |
CN102803247B (zh) | 2014-11-05 |
TWI462915B (zh) | 2014-12-01 |
CA2766154C (en) | 2015-04-07 |
CA2766154A1 (en) | 2010-12-29 |
RU2537847C2 (ru) | 2015-01-10 |
JP2012531424A (ja) | 2012-12-10 |
MX2011012824A (es) | 2012-01-27 |
CO6480943A2 (es) | 2012-07-16 |
AU2010264422A1 (en) | 2012-02-02 |
EP2445899A1 (en) | 2012-05-02 |
ZA201108838B (en) | 2012-08-29 |
PE20121403A1 (es) | 2012-11-02 |
US20120149728A1 (en) | 2012-06-14 |
EP2445899B1 (en) | 2016-05-11 |
WO2010151611A1 (en) | 2010-12-29 |
IL216924A0 (en) | 2012-03-01 |
US8664245B2 (en) | 2014-03-04 |
KR20120039555A (ko) | 2012-04-25 |
NZ597219A (en) | 2013-05-31 |
TN2011000620A1 (en) | 2013-05-24 |
JP6053519B2 (ja) | 2016-12-27 |
MA33378B1 (fr) | 2012-06-01 |
AR077223A1 (es) | 2011-08-10 |
BRPI1011258A2 (pt) | 2016-03-22 |
PL2445899T3 (pl) | 2017-08-31 |
SG176645A1 (en) | 2012-01-30 |
RU2012102671A (ru) | 2013-08-10 |
KR101804749B1 (ko) | 2017-12-05 |
UY32738A (es) | 2011-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10963A (es) | Compuestos de 2-amino pirimidina | |
NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
NI201000059A (es) | Inhibidores de la cinasa c-fms. | |
DOP2011000398A (es) | Nuevas sales de fumarato de un antagonista del receptor de histamina h3 | |
UY32296A (es) | Nuevos compuestos | |
ECSP11011294A (es) | Compuestos de anillo fusionados y su uso | |
EA201290355A1 (ru) | Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1 | |
ECSP088700A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
EA201590823A1 (ru) | 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора | |
EA201600436A1 (ru) | Кристаллическая солевая форма (s)-(2-(6-хлор-7-метил-1h-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора | |
DK2148873T3 (da) | 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister | |
SV2011003854A (es) | Derivados de piperazina que se unen a las placas amiloides para obtener imagenes de las mismas y su uso | |
UY32042A (es) | Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90 | |
CL2012002451A1 (es) | Procedimientos para preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida; uno de sus compuestos intermediarios; y la preparacion del mismo. | |
CY1118841T1 (el) | Παραγωγα αμινοκυκλοβουτανιου, μεθοδος παρασκευης αυτων και η χρηση αυτων ως φαρμακα | |
BR112012030004A2 (pt) | antagonistas não competitivos de receptor nicotínico | |
AR090605A1 (es) | Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer | |
AR069009A1 (es) | Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosina | |
ECSP11011547A (es) | Nuevas sales de fumarato de un antagonista del receptor de histamina h3 | |
NI201100210A (es) | Nuevas sales de fumarato de un antagonista del receptor de histamina h3. | |
UA106380C2 (ru) | Фумаратные соли антагониста гистаминового рецептора н3 | |
EA201301136A3 (ru) | Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей | |
EA201390966A1 (ru) | Замещенные соединения [(5h-пирроло[2,1-c][1,4]бензодиазепин-11-ил)пиперазин-1-ил]-2,2-диметилпропановой кислоты в качестве обратных агонистов h1/антагонистов 5-htдвойного действия | |
CL2018000256A1 (es) | Nueva asociación entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr. | |
NI201200127A (es) | Procedimiento para la preparación de 2 - ( ciclohexilmetil ) - n - { 2 - [ (2s) - 1 - metilpirrolidin - 2 - il ] etil } - 1, 2, 3, 4 - tetrahidroisoquinolin - 7 - sulfonamida. |